Across TCGA pan-cancer cohorts, FPGS mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FPGS data layer compared with 24 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FPGS mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FPGS expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.
HNSC, PDAC, and LSCC are the cancer types where FPGS mass-spec protein most reproducibly stratifies survival.